Clinical Trial Update: CKM For Safe Use of SGLT2i in Type 1 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update on CKM for the safe use of SGLT2 inhibitors in individuals with Type 1 diabetes; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• SGLT2 inhibitors (class)

Snippet

Sponsor: University of California, San Diego | Conditions: Type 1 Diabetes (T1D) | Phase 3 | Status: NOT_YET_RECRUITING